Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1927 1
1952 1
1967 1
1976 1
1983 1
1984 1
1985 1
1987 1
1988 2
1990 5
1992 1
1993 1
1994 4
1995 4
1996 2
1997 2
1998 5
1999 8
2000 7
2001 15
2002 14
2003 14
2004 22
2005 13
2006 21
2007 15
2008 23
2009 15
2010 15
2011 15
2012 16
2013 17
2014 34
2015 49
2016 46
2017 61
2018 77
2019 77
2020 110
2021 173
2022 164
2023 191
2024 44

Text availability

Article attribute

Article type

Publication date

Search Results

1,146 results

Results by year

Filters applied: . Clear all
Page 1
Occupational Hand Dermatitis.
Karagounis TK, Cohen DE. Karagounis TK, et al. Curr Allergy Asthma Rep. 2023 Apr;23(4):201-212. doi: 10.1007/s11882-023-01070-5. Epub 2023 Feb 7. Curr Allergy Asthma Rep. 2023. PMID: 36749448 Free PMC article. Review.
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
Yosipovitch G, Mollanazar N, Ständer S, Kwatra SG, Kim BS, Laws E, Mannent LP, Amin N, Akinlade B, Staudinger HW, Patel N, Yancopoulos GD, Weinreich DM, Wang S, Shi G, Bansal A, O'Malley JT. Yosipovitch G, et al. Nat Med. 2023 May;29(5):1180-1190. doi: 10.1038/s41591-023-02320-9. Epub 2023 May 4. Nat Med. 2023. PMID: 37142763 Free PMC article. Clinical Trial.
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial.
Weidinger S, Bieber T, Cork MJ, Reich A, Wilson R, Quaratino S, Stebegg M, Brennan N, Gilbert S, O'Malley JT, Porter-Brown B. Weidinger S, et al. Br J Dermatol. 2023 Oct 25;189(5):531-539. doi: 10.1093/bjd/ljad240. Br J Dermatol. 2023. PMID: 37463508 Free article. Clinical Trial.
Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
Gulliver W, Zouboulis CC, Prens E, Jemec GB, Tzellos T. Gulliver W, et al. Rev Endocr Metab Disord. 2016 Sep;17(3):343-351. doi: 10.1007/s11154-016-9328-5. Rev Endocr Metab Disord. 2016. PMID: 26831295 Free PMC article. Review.
Evidence-based medical treatment of mild disease consists of topical Clindamycin 1 % solution/gel b.i.d. for 12 weeks or Tetracycline 500 p.o. b.i.d. for 4 months (LOE IIb, SOR B), for more widespread disease. If patient fails to exhibit response to treatment or for a PGA …
Evidence-based medical treatment of mild disease consists of topical Clindamycin 1 % solution/gel b.i.d. for 12 weeks or Tetracycline 500 p. …
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA, Deleuran M, Bissonnette R, de Bruin-Weller M, Galus R, Nakahara T, Seo SJ, Khokhar FA, Vakil J, Xiao J, Marco AR, Levit NA, O'Malley JT, Shabbir A. Beck LA, et al. Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3. Am J Clin Dermatol. 2022. PMID: 35503163 Free PMC article.
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, Browning J, Soong W, Sun X, Chen Z, Kosloski MP, Kamal MA, Delevry D, Chuang CC, O'Malley JT, Bansal A. Blauvelt A, et al. Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14. Am J Clin Dermatol. 2022. PMID: 35567671 Free PMC article. Clinical Trial.
1,146 results